Apollo Endosurgery to Participate in Digestive Disease Week® 2019

AUSTIN, Texas–(BUSINESS WIRE)–Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq: APEN), a global leader in
less invasive medical devices for gastrointestinal and bariatric
procedures, announced today its participation during Digestive Disease
Week 2019 (“DDW”). DDW will be held May 18-21, 2019 at the San Diego
Convention Center in San Diego, California.

Apollo’s OverStitch™ Endoscopic Suturing System and ORBERA® Intragastric
Balloon, will be featured in 40 clinical presentations that demonstrate
the effectiveness of OverStitch and ORBERA when used across a number of
diverse clinical needs.

Apollo will also feature Overstitch Sx, its latest endoscopic suturing
device designed for compatibility with single-channel endoscopes with
diameters ranging from 8.8mm to 9.8mm. The Overstitch Sx provides a
greater number of physicians with access to the benefits of
full-thickness flexible endoscopic suturing regardless of their
hospital’s selection of endoscopic capital equipment or endoscope

In addition, Apollo will unveil Apollo Care, a nutritional and
activity-based patient management platform designed to provide
physicians and dietitians the ability to deliver personalized weight
loss coaching programs to their patients without the need for frequent
in-office visits.

During the conference, DDW will host hands-on workshops for its
attendees including sessions that feature the OverStitch and ORBERA
technologies. In addition, the Apollo Mobile Learning Center will be in
San Diego to support personalized hands-on physician training. The
Apollo Mobile Learning Center is a state-of-the-art mobile training
facility that allows for advanced endoscopic training programs to be
conducted in individual local markets.

About OverStitch™

The OverStitch endoscopic suturing system enables advanced endoscopic
surgery by allowing physicians to place full-thickness sutures from a
flexible endoscope. This new technology enables a secure approximation
of tissue endoscopically and a wide range of less invasive solutions for
physicians who treat defects in both the upper and lower GI tract of
their patients. Additionally, physicians are leveraging endoscopic
suturing to perform a variety of advanced bariatric procedures. For more
information regarding OverStitch go to: www.overstitch.com.


ORBERA® is an incision-less, non-surgical weight loss solution designed
for adult patients suffering from obesity, who are not appropriate for
or considering invasive surgery, but for whom diet and exercise or
pharmaceutical interventions have not worked.

In a non-surgical (endoscopic) procedure, the thin and deflated ORBERA
balloon is placed into the stomach. It is then filled with saline until
it’s about the size of a grapefruit. The procedure typically takes about
20 to 30 minutes and the patient can generally go home the same day. At
six months, through another non-surgical procedure, the ORBERA balloon
is deflated and then removed.

Once the balloon is in place, the patient receives an individually
tailored support program through the ORBERA Managed Weight Loss System
team of experts to help keep them motivated, coordinate their program
and help them work through weight loss barriers to meet their long-term
weight loss goals. Coaching takes place over 12 months, even though the
balloon is removed after six months. The program is designed to help the
patient develop sustainable, healthy habits that will help keep weight
off over time.

For more than 20 years, the global medical community has been using
intragastric balloons from the makers of ORBERA to help thousands of
people lose weight. More than 295,000 ORBERA balloons have been
distributed worldwide in over 70 countries.

For additional information regarding ORBERA, please visit www.orbera.com.

For full safety information please visit www.orbera.com/dfu,
talk with your doctor, or call Apollo Customer Support at 1-855-MYORBERA.

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. is a medical technology company focused on less
invasive therapies to treat various gastrointestinal conditions, ranging
from gastrointestinal defect repairs to the interventional treatment of
obesity. Apollo’s device-based therapies are an alternative to invasive
surgical procedures, thus lowering complication rates and reducing total
healthcare costs. Apollo’s products are offered in over 70 countries
today and include the OverStitch™ Endoscopic Suturing System, the
OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric

Apollo’s common stock is traded on Nasdaq Global Market under the symbol
“APEN.” For more information regarding Apollo, go to: www.apolloendo.com.

© 2018 Apollo Endosurgery, Inc. All rights reserved. Any third-party
trademarks used herein are the property of their respective owners.

Cautionary Note on Forward-Looking Statements

Certain statements in this press release are forward-looking statements
that are subject to risks and uncertainties that could cause results to
be materially different than expectations. Important factors that could
cause actual results to differ materially include: the advancement of
Apollo products; development of enhancements to Apollo’s existing
products and technologies; market acceptance of Apollo’s products; the
execution of our gross margin improvement projects; the ability to
collect future payments from ReShape; and statements relating to the
availability of cash for Apollo’s future operations; Apollo’s ability to
support the adoption of its products and its ability to broaden its
product portfolio as well as other factors detailed in Apollo’s periodic
reports filed with the Securities and Exchange Commission, or SEC,
including its Form 10-K for the year ended December 31, 2018 and its
Form 10-Q for the three months ended March, 31, 2019. Copies of reports
filed with the SEC are posted on Apollo’s website and are available from
Apollo without charge. These forward-looking statements are not
guarantees of future performance and speak only as of the date hereof,
and, except as required by law, Apollo disclaims any obligation to
update these forward-looking statements to reflect future events or


Media Contact:
Jen Cook, 512-279-5158
[email protected]

Investor Contacts:
John Gillings, 512-279-5100
Relations Manager
[email protected]

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.